Section Arrow
CTSO.NASDAQ
- Cytosorbents Corp
(Financial Status)
Quotes are at least 15-min delayed:2026/01/23 08:41 EST
Pre Market
Last
 0.73
+0.0538 (+7.96%)
Bid
0.68
Ask
0.73
High 0.73 
Low 0.69 
Volume 198 
Regular Hours (Closed)
Last
 0.6762
-0.0049 (-0.72%)
Day High 
0.70705 
Prev. Close
0.6811 
1-M High
0.766 
Volume 
78.24K 
Bid
0.68
Ask
0.73
Day Low
0.6744 
Open
0.6784 
1-M Low
0.616 
Market Cap 
42.78M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.69 
20-SMA 0.69 
50-SMA 0.69 
52-W High 1.61 
52-W Low 0.6 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.18/-0.06
Enterprise Value
69.22M
Balance Sheet
Book Value Per Share
0.14
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
35.59M
Operating Revenue Per Share
0.48
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ABTAbbott Laboratories108.61-12.12-10.04%15.3PE
Pre Market 109.06 +0.45 +0.41%
BSXBoston Scientific Corp91.29-0.42-0.46%49.04PE
Pre Market 91.16 -0.13 -0.14%
DXCMDexCom73.92+1.81+2.51%39.94PE
Pre Market 73.91 -0.01 -0.01%
PACBPacific Biosciences of California2.67+0.25+10.33%-- 
Pre Market 2.6376 -0.0324 -1.21%
MDTMedtronic plc101.34+1.05+1.05%27.2PE
Pre Market 101.2 -0.14 -0.14%
Industry overview quotes are at least 15 minutes delayed
Business Description
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.